News

Identifying Elevated Rates of CDR Scoring Errors: The Cognitive-Functional Difference Score

At 10th Clinical Trials on Alzheimer’s Disease (CTAD) MedAvante-ProPhase presented research and analysis addressing the need to identify administrations of the Clinical Dementia Rating scale (CDR) within clinical trials that have an increased probability of scoring errors to maintain data integrity and improve signal detection.

Continue reading

Subjective Interview Quality Metrics Predict Scoring Performance in the Administration of the PANSS

MedAvante presented research at the 30th European College of Neuropsychopharmacology (ECNP) Congress showing that subjective interview quality metrics are predictive of in-study scoring performance and can serve as a useful tool in ongoing monitoring of raters in the administration and scoring of the PANSS. When combined with eCOA administration to improve standardization, subjective quality metrics can increase signal detection in global schizophrenia clinical trials.

Continue reading

Impact of Centralized Over-Read on Outcomes in Depression and Schizophrenia Trials

Research presented at the 2017 International Society for CNS Clinical Trials and Methodology (ISCTM) Fall Conference examined Central Review of two widely used efficacy measures administered in schizophrenia and depression trials, the Positive and Negative Syndrome Scale (PANSS) and Hamilton Depression Rating Scale (HAM-D), resulting in positive impact on individual item scores and total scale score for key study visits, improving interrater reliability and reducing rater drift.

Continue reading

The RBANS as a Useful Outcome Measure in Prodromal AD Trials

The RBANS total scale index score correlated with the CDR-SB, and decreased in a linear fashion with increasing CDR-SB, even within a limited range of CDR-SB scores and without evidence of floor or ceiling effects.

Continue reading

Increased Signal Detection in Alzheimer’s Disease Clinical Trials

Research presented at 2017 Alzheimer’s Association International Conference (AAIC) demonstrates that increased lag time between administrations of COAs significantly increases error rates on three of the most commonly used and complex measures in AD clinical trials.

Continue reading

PANSS and CGI-S: Ten Years Later

Analysis provides additional evidence of substantial agreement between PANSS total score and CGI-S rating; brings into question the additional value of CGI-S administration in view of its limitations including expectancy bias, ceiling effects, and lack of reliability data.

Continue reading